The company has planned a registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in Phase 1/2 clinical trial.
The $50 Goldman Sachs price target compares with a $40.25 consensus. Both targets indicate plenty of room to run from the recent share closing price of $6.86. In fact, hitting the Goldman Sachs target would be a remarkable 625% gain.
This is another microcap biotech that has been hammered but has huge upside to the Goldman Sachs target. Silverback Therapeutics Inc. (NASDAQ: SBTX) is a clinical-stage biopharmaceutical company that develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase 1/1b clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric and non-small cell lung cancers.
The company also focuses on developing SBT6290, a product candidate that is in the preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck and non-small cell lung cancers. In addition, it is developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads.
For full disclosure, it should be noted that Silverback has class action suits pending, according to reports. However, that is hardly unusual when clinical trials hit some speed bumps.
Note that the Goldman Sachs price objective of $25 is less than the $36.80 consensus target. However, shares closed trading at $3.88 on Friday, so the Goldman Sachs target represents a gain of over 500%.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.